A compound having the structure formula (I) or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
1. A compound of the formula I:
wherein
X is a bond or —O—C 1-6 alkylene-, wherein C 1-6 alkylene is unsubstituted, mono-substituted at any carbon with C 1-6 alkyl, or independently disubstituted at different carbons with C 1-6 alkyl;
W is selected from the group consisting of
wherein N is attached to
and
R is selected form the group consisting of C 1-6 alkyl and C 3-6 cycloalkyl,
or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 , wherein X is a bond or —OCH 2 —, or a pharmaceutically acceptable salt thereof.
3. A compound of claim 1 , wherein R is selected from the group consisting of methyl, ethyl, propyl, isopropyl, 2-methylpropyl, butyl, 3-methylbutyl, pentyl and pentan-2-yl, or a pharmaceutically acceptable salt thereof.
4. A compound of claim 1 , selected from the group consisting of
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-butoxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-methoxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-ethoxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-isopropyloxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-2-methylpropoxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-propoxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-pentoxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-3-methylbutoxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-pentan-2-yloxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-((Z)-{[(2S)-2-methylbutyl]oxy}-NNO-azoxy)-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-cyclohexyloxy-NNO-azoxy]-L-prolinate,
(3S)-3-(4-Chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(Z)-butoxy-NNO-azoxy]piperidine-4-carboxylate,
{(2S)-1-[(E)-butoxy-NNO-azoxy]pyrrolidin-2-yl}methyl(3S)-3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl carbonate, and
(3S)-3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl 1-[(E)-(cyclohexyloxy)-NNO-azoxy]piperidine-2-carboxylate
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising a compound of claim 1 , a diuretic, and a pharmaceutically acceptable carrier.
8. A method for treating hypertension in a patient which comprises administering to the patient a therapeutically effective amount of the composition of claim 5 .